RegeniTherix™ ability to detect & quantify prognostic biomarkers is highlighted in new publication

Fundamental research into RegeniTherix™ technology published

RegeniTherix™ combines therapeutic (scaffold) and diagnostic (hydrogel capture of biomarkers) technologies. Scaffold and hydrogel components are designed to work together to facilitate the collection and sampling of biomarkers produced by the patient’s ingressing cells involved in the wound healing process. RegeniTherix™ is an accurate and minimally invasive method to sample wound biomarkers and gain information on the prospects that a particular wound will heal.

Neotherix is delighted that this paper supports the onward development of the product and welcomes any approach from interested partners.

We would like to thank our collaborators at University of York for their work on this project.

Full Article Available Online: Biosensors and Bioelectronics, Volume 242, 15 December 2023, 115743

Abstract:   Chronic wounds present a major healthcare burden, yet most wounds are only assessed superficially, and treatment is rarely based on the analysis of wound biomarkers. This lack of analysis is based on the fact that sampling of wound biomarkers is typically invasive, leading to a disruption of the wound bed while biomarker detection and quantification is performed in a remote laboratory, away from the point of care. Here, we introduce the diagnostic element of a novel theranostic system that can non-invasively sample biomarkers without disrupting the wound and that can perform biomarker quantification at the point of care, on a short timescale. The system is based on a thermally switchable hydrogel scaffold that enhances wound healing through regeneration of the wound tissue and allows the extraction of wound biomarkers non-destructively. We demonstrate the detection of two major biomarkers of wound health, i.e., IL-6 and TNF-α, in human matrix absorbed into the hydrogel dressing. Quantification of the biomarkers directly in the hydrogel is achieved using a chirped guided mode resonant biosensor and we demonstrate biomarker detection within the clinically relevant range of pg/mL to μg/mL concentrations. We also demonstrate the detection of IL-6 and TNF-α at concentration 1 ng/mL in hydrogel dressing absorbed with clinical wound exudate samples. The high sensitivity and the wide dynamic range we demonstrate are both essential for the clinical relevance of our system. Our test makes a major contribution towards the development of a wound theranostic for guided treatment and management of chronic wounds.